4 / 32
advanced NSCLC
PDL1 status
Molecular
PD-L1≥ 50%
PD-L1< 50%
EGFR ALK
ROS1
BRAF
V600E HER2
NTRK MET
1
ST
LINE
Pembrolizumab
*,#
Platinum based-CT
+/- bevacizumab
*#
,
And maintenance;
CBDCA/Pem/Pembr*
Platinum based-CT
+/- necitumumab
*,#
Crizotinib
*,#
Ceritinib
@
Entrectinib
@
2
ND
LINE
•
Nivolumab
*#
•
Atezolizumab
*#
•
Pembrolizumab
*
#
If PD-L1 +
•
Docetaxel +
Ramucirumab
*,#
Platinum
based-CT
•
Nivolumab
*#
•
Atezolizumab
*#
•
Pembrolizumab
*#
If PD-L1 +
•
Docetaxel +
Nintedanib
#
/ Ramu
*,#
T790M
+
à
Osimertinib
*#
(if not received as 1
st
Line)
T790M
– or 1
st
Line Osimertinib
à
Pem / Platinum
Ceritinib
*#
Alectinib
#*
Brigatinib
*
Lorlatinib
*
Afatinib
*,#
Erlotinib
*,#
+/- BVZ
#
Gefitinib
*,#
Dacomitinib
@
Osimertinib
@
Crizotinib
*,#
Ceritinib
*#
Alectinib
#
Dabrafenib
+
Trametinib
*#
2018:
Entrectinib
*,#
LOXO101
*
Trastuzumab
@
TDM1
@
…
Crizotinib
@
Platinum based-CT
Squamous
Non-Squamous
*FDA approved
#
EMA approved
@
Not yet approved
PD-L1
Oncogene addiction
50%